Alnylam Pharmaceuticals, Inc. (ALNY) vs argenex SE (ARGX)
Alnylam Pharmaceuticals, Inc. and argenex SE are both Biotechnology companies. argenex SE is the larger, with a market value of $60.2B against $31.2B — 1.9× the size. argenex SE trades at the lower P/E: 34.6× against 43.6×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 70.6%. argenex SE has the higher net margin (32.2% vs 16.1%) and the higher return on invested capital (20.7% vs 0.00%). Across the 21 metrics below, argenex SE leads on 12 and Alnylam Pharmaceuticals, Inc. on 9.
Valuation
Profitability
| Metric | ALNY | ARGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 79.65% | 90.15% | 65.16% |
| Operating margin | 20.81% | 30.06% | 0.00% |
| Net margin | 16.13% | 32.20% | 0.00% |
| Free cash flow margin | 17.07% | 25.87% | 0.00% |
| Return on equity | 96.55% | 27.07% | (57.72%) |
| Return on assets | 15.30% | 19.95% | (49.22%) |
| Return on invested capital | 0.00% | 20.71% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack